Adjunctive Ketamine for Sedation in Critically Ill Mechanically Ventilated Patients: An Active-Controlled, Pilot, Feasibility Clinical Trial - Amer, Marwa; Maghrabi, Khalid; Bawazeer, Mohammed; Alshaikh, Kamel; Shaban, Mohammad; Rizwan, Muhammad; Amin, Rashid; De Vol, Edward; Baali, Mawadah; Altewerki, Malak; Bano, Mehreen; Alkhaldi, Fawziah; et al. (medRxiv, 2021)
Objective Ketamine has been shown to decrease sedative requirements in intensive care unit (ICU). Randomized trials are limited on patient-centered outcomes. We designed this pilot clinical trial to evaluate the feasibility of using ketamine as an adjunct analgosedative compared with standard of care (SOC) alone and determine preliminary effect size on 28-day mechanical ventilation (MV) duration and ventilator-free days (VFDs).Design Pilot, single-center, active-controlled, open-label, randomized clinical trial.Setting Medical, surgical, and transplant ICUs at King Faisal Specialist Hospital and Research Center, Saudi Arabia.Patients and Methods Adult patients who were intubated within 24 hours, expected to require MV for the next calendar day, and had institutional pain and sedation protocol initiated.Intervention Adjunct ketamine infusion 1-2 μg/kg/min for 48 hours versus SOC.Measurements and Main Results Total of 83 patients (43 in SOC and 40 in ketamine) were included. Demographics were balanced between groups. Median MV duration was 7 (interquartile range [IQR] 3-9.25 days) in ketamine and 5 (IQR 2-8 days) in SOC, p= 0.15. Median VFDs was 19 (IQR 0-24.75 days) in ketamine and 19 (IQR 0-24 days) in the SOC (p=0.70). More patients attained goal RASS score at 24 and 48 hours in ketamine (67.5% and 73.5%, respectively) compared with SOC (52.4% and 66.7%, respectively). Sedatives and vasopressors cumulative doses, and hemodynamic changes were similar. ICU length-of-stay was 12.5 (IQR 6-21.2 days) in ketamine, compared with 12 (IQR 5.5-23 days) in SOC, p=0.89. Consent and protocol adherence rate were adequate. No serious adverse events were observed in either group.Conclusions Use of ketamine as an adjunct analgosedative agent appeared to be feasible and safe with no negative impact on outcomes, including hemodynamics. The protocol of this pilot trial could be improved by modifying ketamine dosing regimen. These findings provide a basis for future, adequately powered, multicenter trial to investigate its association with patient-centered outcomes further.Competing Interest StatementThe authors have declared no competing interest.Clinical TrialNCT04075006Funding StatementNo funding. This trial was investigator-initiated and all study authors are employees at King Faisal Specialist Hospital and Research Center (KFSH&RC), which has not provided any research grant for this particular project. All authors volunteered their time and used local resources to conduct the study.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The study was conducted in accordance with the principles of the Declaration of Helsinki. Our institution [King Faisal Specialist Hospital and Research Center (KFSH&RC)] research ethics committee (REC) and office of research affair approved the study with the Research Advisory Council (RAC) number 2191 187. Given the need to enroll patients in an expedited manner within the 24-hour window, verbal consent from a guardian/next of kin was allowed and documented in the chart. Written consent was obtained as soon as the next of kin became available. During the COVID-19 pandemic, where patients family visits were prohibited, we were unable to obtain written consent. Therefore, we granted approval from our research ethics committee for the following consenting process: verbal consent from the family over the phone or a conference call to explain the nature of the study, as detailed in the written informed consent. A witness who was not part of this research study was present during the verbal consenting process and documentation was completed in the patient chart. All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).Yes I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe datasets used and analyzed during the current report are available from the corresponding author on reasonable request.